eligibility_summary
Include: early MS per McDonald 2017 with dissemination in time and symptom onset ≤2 years. Women who can become pregnant must abstain or use effective contraception during treatment and 6 months after. Exclude: progressive MS, MRI contraindication, pregnancy/lactation, chronic steroids/immunosuppressants, major comorbidities/NYHA ≥III, infection, malignancy, prior high‑efficacy DMTs or recent fumarates, recent systemic steroids, abnormal labs, mAb allergy, no venous access.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Ocrelizumab (Ocrevus) — a humanized IgG1 monoclonal antibody targeting CD20 on B cells. Mechanism: depletes CD20+ B cells (pre‑B to mature/memory, spares stem cells/plasma cells) via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and apoptosis, reducing B‑cell antigen presentation, costimulation, and pro‑inflammatory cytokines that drive MS relapses. Comparator: placebo infusions after initial open‑label ocrelizumab. Targets/pathways: CD20+ B cells (peripheral and CNS‑trafficking), with downstream modulation of T‑cell activation and myeloid‑mediated inflammation, immune reconstitution profiling of B, T, and myeloid cells, biomarkers include B‑cell counts and neurofilament light chain. Objective: test if stopping ocrelizumab after early intensive therapy sustains remission vs continued B‑cell depletion.